What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?

被引：4

作者：

Komrokji, Rami ^{[1
]}

Al Ali, Najla ^{[1
]}

Padron, Eric ^{[1
]}

Lancet, Jeffrey ^{[1
]}

Nazha, Aziz ^{[2
]}

Steensma, David ^{[3
]}

DeZern, Amy ^{[4
]}

Roboz, Gail ^{[5
]}

Garcia-Manero, Guillermo ^{[6
]}

Sekeres, Mikkael A. ^{[2
]}

Sallman, David ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, 12902 Magnolia Dr, Tampa, FL 33612 USA

[2] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Johns Hopkins Univ, Kimmel Canc Ctr, Baltimore, MD USA

[5] Weill Cornell Med Coll, New York, NY USA

[6] MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 11期

关键词：

Myelodysplastic syndromes; higher risk disease; hypomethylating agents; optimal timing of treatment; CONVENTIONAL CARE REGIMENS; SCORING SYSTEM; AZACITIDINE;

D O I：

10.1080/10428194.2021.1938028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hypomethylating agents (HMAs) are the standard of care for higher risk MDS (HR-MDS) patients. The current dogma is to begin HMA therapy in all HR-MDS patients at the time of initial diagnosis. We investigated the impact of the timing of HMA initiation among HR-MDS patients presenting with adequate blood counts to discern the possible benefit of early treatment based solely on disease risk. We identified 320 HR-MDS patients with adequate hematopoiesis who were treated with HMA. The complete response rates were 21%, 26%, 23%, and 7% respectively for patients treated within 30, 31-60, 61-90, and more than 90 days from time of diagnosis (p=.046). The median OS from the date of diagnosis was 641, 550, 979, and 806 days, respectively (p=.2). A delay in initiating HMA therapy in HR-MDS patients with adequate blood counts is not associated with worsened outcomes.

引用

页码：2762 / 2767

页数：6

共 14 条

[1] Clinical Effect of Point Mutations in Myelodysplastic Syndromes [J].

Bejar, Rafael ;

Stevenson, Kristen ;

Abdel-Wahab, Omar ;

Galili, Naomi ;

Nilsson, Bjoern ;

Garcia-Manero, Guillermo ;

Kantarjian, Hagop ;

Raza, Azra ;

Levine, Ross L. ;

Neuberg, Donna ;

Ebert, Benjamin L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2496-2506

[2] Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia [J].

Cheson, Bruce D. ;

Greenberg, Peter L. ;

Bennett, John M. ;

Lowenberg, Bob ;

Wijermans, Pierre W. ;

Nimer, Stephen D. ;

Pinto, Antonio ;

Beran, Miloslav ;

de Witte, Theo M. ;

Stone, Richard M. ;

Mittelman, Moshe ;

Sanz, Guillermo F. ;

Gore, Steven D. ;

Schiffer, Charles A. ;

Kantarjian, Hagop .

BLOOD, 2006, 108 (02) :419-425

[3] A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome [J].

Cutler, CS ;

Lee, SJ ;

Greenberg, P ;

Deeg, HJ ;

Pérez, WS ;

Anasetti, C ;

Bolwell, BJ ;

Cairo, MS ;

Gale, RP ;

Klein, JP ;

Lazarus, HM ;

Liesveld, JL ;

McCarthy, PL ;

Milone, GA ;

Rizzo, JD ;

Schultz, KR ;

Trigg, ME ;

Keating, A ;

Weisdorf, DJ ;

Antin, JH ;

Horowitz, MM .

BLOOD, 2004, 104 (02) :579-585

[4] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

[5] Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial [J].

Garcia-Manero, Guillermo ;

Fenaux, Pierre ;

Al-Kali, Aref ;

Baer, Maria R. ;

Sekeres, Mikkael A. ;

Roboz, Gail J. ;

Gaidano, Gianluca ;

Scott, Bart L. ;

Greenberg, Peter ;

Platzbecker, Uwe ;

Steensma, David P. ;

Kambhampati, Suman ;

Kreuzer, Karl-Anton ;

Godley, Lucy A. ;

Atallah, Ehab ;

Collins, Robert, Jr. ;

Kantarjian, Hagop ;

Jabbour, Elias ;

Wilhelm, Francois E. ;

Azarnia, Nozar ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2016, 17 (04) :496-508

[6] Time-dependent decision analysis: Stable disease in azacitidine (AZA)-treated patients (pts) with higher-risk MDS [J].

Gore, S. ;

Fenaux, P. ;

Santini, V. ;

Bennett, J. M. ;

Silverman, L. R. ;

Seymour, J. F. ;

Hellstrom-Lindberg, E. ;

Swern, A. S. ;

Beach, C. L. ;

List, A. F. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[7] A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial [J].

Gore, Steven D. ;

Fenaux, Pierre ;

Santini, Valeria ;

Bennett, John M. ;

Silverman, Lewis R. ;

Seymour, John F. ;

Hellstrom-Lindberg, Eva ;

Swern, Arlene S. ;

Beach, Charles. L. ;

List, Alan. F. .

HAEMATOLOGICA, 2013, 98 (07) :1067-1072

[8] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

[9] Revised International Prognostic Scoring System for Myelodysplastic Syndromes [J].

Greenberg, Peter L. ;

Tuechler, Heinz ;

Schanz, Julie ;

Sanz, Guillermo ;

Garcia-Manero, Guillermo ;

Sole, Francesc ;

Bennett, John M. ;

Bowen, David ;

Fenaux, Pierre ;

Dreyfus, Francois ;

Kantarjian, Hagop ;

Kuendgen, Andrea ;

Levis, Alessandro ;

Malcovati, Luca ;

Cazzola, Mario ;

Cermak, Jaroslav ;

Fonatsch, Christa ;

Le Beau, Michelle M. ;

Slovak, Marilyn L. ;

Krieger, Otto ;

Luebbert, Michael ;

Maciejewski, Jaroslaw ;

Magalhaes, Silvia M. M. ;

Miyazaki, Yasushi ;

Pfeilstoecker, Michael ;

Sekeres, Mikkael ;

Sperr, Wolfgang R. ;

Stauder, Reinhard ;

Tauro, Sudhir ;

Valent, Peter ;

Vallespi, Teresa ;

van de Loosdrecht, Arjan A. ;

Germing, Ulrich ;

Haase, Detlef .

BLOOD, 2012, 120 (12) :2454-2465

[10]

Komrokji RS, 2015, BLOOD, V126

← 1 2 →